Edward Fiorentino
Senseonics HoldingsAbout Edward J. Fiorentino
Edward J. Fiorentino (age 66) has served on Senseonics’ Board since 2015 (previously on Senseonics, Incorporated’s board from 2012–2015). He is Executive Chairman of TerSera Therapeutics (since Jan 2024) and formerly served as Chairman/CEO of TerSera (2016–2023), Crealta (2013–2016), and Actient (2009–2013). He spent over 20 years at Abbott in senior roles, including Corporate VP of Pharmaceutical Commercial Operations, and previously served as SVP & President of Abbott Diabetes Care and EVP of TAP Pharmaceuticals; he holds a B.S. from SUNY and an MBA from Syracuse University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| TerSera Therapeutics | Executive Chairman | Jan 2024–present | Oversight of specialty pharma; continuity from prior CEO role |
| TerSera Therapeutics | Chairman & CEO | 2016–Dec 2023 | Led specialty pharma strategy and execution |
| Crealta Pharmaceuticals | Chairman & CEO | 2013–2016 | Specialty pharma leadership |
| Actient Pharmaceuticals | CEO | 2009–2013 | Specialty pharma leadership |
| Abbott Laboratories | Corporate VP, Pharmaceutical Commercial Operations | >20 years (various) | Led commercial operations; prior SVP & President, Abbott Diabetes Care |
| TAP Pharmaceuticals | Executive Vice President | Prior to 2009 | Senior executive role in pharma JV |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| TerSera Therapeutics | Executive Chairman | Jan 2024–present | Specialty pharma; no public board status disclosed |
Board Governance
- Independence: The Board determined Mr. Fiorentino is an independent director under NYSE American rules .
- Committee assignments (2024): Audit Committee member; Compensation Committee member; not a chair .
- Attendance: Board met 4 times in 2024; each director attended ≥75% of Board and committee meetings; independent directors held regular executive sessions .
- Committee meeting cadence (2024): Audit 8; Compensation 4; Nominating & Corporate Governance 2 .
- Board leadership: Independent Chairman (Stephen DeFalco); CEO and Chair roles separated to strengthen oversight .
Fixed Compensation
| Component | Amount (USD) | Detail | 2024 Notes |
|---|---|---|---|
| Board retainer (cash) | $40,000 | Standard non-employee director annual retainer | Elected to receive fees in equity; see below |
| Audit Committee member fee | $10,000 | Annual member retainer | 2024 member |
| Compensation Committee member fee | $6,500 | Annual member retainer | 2024 member |
| Total cash-equivalent fees | $56,500 | Sum of above (no meeting fees) | Received fully vested RSUs covering 130,507 shares in lieu of $56,500 cash |
| Reported fees earned (proxy table) | $56,500 | 2024 director compensation table | — |
- 2024 total director compensation: $169,000 (fees $56,500; stock awards $112,500) .
Performance Compensation
| Equity Award | Grant Size | Grant Date/Context | Vesting Schedule |
|---|---|---|---|
| Annual RSU grant | 236,344 RSUs | Granted at 2024 annual meeting; standard non-employee director award valued at $112,500 | Vests in full on earlier of May 22, 2025 or 2025 Annual Meeting, subject to continued service |
| Equity in lieu of cash fees | 130,507 fully vested RSUs | Quarterly fee replacement in 2024 | Fully vested upon grant (in lieu of cash) |
- Director equity awards are time-based; no performance-conditioned metrics or targets apply to director compensation at SENS .
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Current public company boards | None disclosed in SENS proxy biography |
| PHC/Ascensia board presence | Two distributor-affiliated directors (Brian Hansen, Ascensia CGM President; Koichiro Sato, PHC COO) designated under investor rights; potential influence on distribution economics |
| Related party exposure (company-level) | Ascensia exclusive distribution drives 82% of 2024 and 93% of 2023 net revenue; tiered revenue sharing mid-teens to mid-40s; balances due/owed reported |
Expertise & Qualifications
- Deep specialty pharma leadership from CEO/Chair roles across TerSera, Crealta, Actient; extensive commercial and operational experience at Abbott (including diabetes care) and TAP Pharmaceuticals .
- Education: B.S. (SUNY) and MBA (Syracuse University) .
- Board-relevant skills: audit committee service; compensation oversight; healthcare commercialization; diabetes device market familiarity .
Equity Ownership
| Metric (as of Apr 1, 2025) | Amount | Breakdown/Notes |
|---|---|---|
| Total beneficial ownership (shares) | 1,525,264 | 967,697 common; 321,223 options exercisable within 60 days; 236,344 RSUs vesting within 60 days |
| Ownership (% of outstanding) | <1% | Company had 654,291,100 shares outstanding; proxy denotes “less than 1%” for this holding |
| Vested vs. unvested | Options noted exercisable within 60 days; RSUs scheduled within 60 days indicate near-term vesting | |
| Pledging/hedging | Prohibited under Insider Trading Policy (no pledging, hedging, short sales, margin) |
Governance Assessment
- Strengths: Independent status; service on Audit and Compensation Committees supports board oversight; consistent attendance; equity-heavy director pay (RSUs) aligns incentives with shareholders; company-wide clawback policy adopted in 2023 enhances accountability; hedging/pledging prohibited .
- Potential risks/RED FLAGS to monitor: Distributor and significant holder influence—Ascensia/PHC arrangements are material to revenues (82% in 2024; 93% in 2023), with PHC holding board designation rights (two seats). While Mr. Fiorentino is independent, board dynamics and committee oversight should continue scrutinizing related-party economics and ensure arm’s-length terms and robust risk oversight .
- Compensation mix: 2024 director compensation skewed toward equity ($112,500 RSU vs $56,500 fees), improving ownership alignment; no director meeting fees; clear committee fee schedule .
- Attendance/engagement: ≥75% attendance and regular independent executive sessions; Audit Committee met 8 times—indicative of active oversight cadence .
Overall, Fiorentino presents as a seasoned, independent healthcare operator with relevant diabetes market credentials and active committee participation. The primary governance sensitivity is Senseonics’ heavy reliance on Ascensia/PHC, requiring continued vigilance on conflicts, pricing tiers, and performance obligations; his Audit and Compensation roles are central to sustaining investor confidence in this context .